Bellicum Pharmaceuticals Inc Revenue Growth Rates (BLCM), Current and Historic Growth - CSIMarket
CSIMarket
 


Bellicum Pharmaceuticals Inc   (BLCM)
 

BLCM's Revenue Growth by Quarter and Year

Bellicum Pharmaceuticals Inc 's Revenue results by quarter and year




BLCM Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September 1.00
2nd Quarter June 0.00
1st Quarter March 0.01
FY 1.01

BLCMs Annual Revenue
Bellicum Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 1.50 millions
Bellicum Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 6.23 millions
Bellicum Pharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 0.89 millions
Bellicum Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 8.49 millions
Bellicum Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 2.76 millions




BLCM Revenue third quarter 2023 Y/Y Growth Comment
Bellicum Pharmaceuticals Inc reported decrease in Revenue in the third quarter 2023 by -0.79% to $ 1.00 millions, from the same quarter in 2022.
The decrease in the third quarter 2023 Bellicum Pharmaceuticals Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 1922.78%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 149 other companies have achieved higher Revenue growth. While Bellicum Pharmaceuticals Inc ' s Revenue decline of -0.79% ranks overall at the positon no. 2214 in the third quarter 2023.




BLCM Revenue ( Y/Y Growth %) 2023
2022 2021 2020
4th Quarter December - -1.96 % 2 % -90.25 %
3rd Quarter September -0.79 % -79.84 % 50000 % -97.67 %
2nd Quarter June - -98.59 % 2266.67 % -98.24 %
1st Quarter March 0 % 0 % -97.14 % -62.37 %
FY   - -75.48 % 601.12 % -

Financial Statements
Bellicum Pharmaceuticals Inc 's third quarter 2023 Revenue $ 1.00 millions BLCM's Income Statement
Bellicum Pharmaceuticals Inc 's third quarter 2022 Revenue $ 1.01 millions Quarterly BLCM's Income Statement


BLCM Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
4th Quarter December - -50.5 % -89.82 % 4900 %
3rd Quarter September - 10000 % 605.63 % -66.67 %
2nd Quarter June - 0 % 7000 % -91.43 %
1st Quarter March -98 % -98.04 % -98 % -93.18 %
FY (Year on Year)   - -75.48 % 601.12 % -




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #150
Healthcare Sector #401
Overall #2214

Revenue Y/Y Growth Statistics
High Average Low
49960 % 1922.78 % -98.35 %
(Sep 30 2021)   (Jun 30 2020)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #150
Healthcare Sector #401
Overall #2214
Revenue Y/Y Growth Statistics
High Average Low
49960 % 1922.78 % -98.35 %
(Sep 30 2021)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Bellicum Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BLCM's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BLCM's III. Quarter Q/Q Revenue Comment


Bellicum Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 1.52 $ 1.53 $ 1.54 $ 1.54 $ 1.55
Y / Y Revenue Growth (TTM) -1.81 % -72.44 % -75.35 % -75.32 % -75.16 %
Year on Year Revenue Growth Overall Ranking # 3648 # 71 # 40 # 26 # 2476
Seqeuential Revenue Change (TTM) -0.59 % -0.65 % -0.07 % -0.52 % -72.1 %
Seq. Revenue Growth (TTM) Overall Ranking # 3670 # 2687 # 2263 # 2747 # 2796


Cumulative Revenue growth Comment
Bellicum Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Bellicum Pharmaceuticals Inc 's annual Revenue drop would be -1.81% year on year to $2 millions.

In the Healthcare sector 543 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 71 to 3648.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 205
Healthcare Sector # 544
Overall # 3648

Revenue TTM Y/Y Growth Statistics
High Average Low
2193.36 %
277.8 %
-93.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 205
Sector # 549
S&P 500 # 3670
Cumulative Revenue growth Comment
Bellicum Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Bellicum Pharmaceuticals Inc 's annual Revenue drop would be -1.81% year on year to $2 millions.

In the Healthcare sector 543 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 71 to 3648.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 205
Healthcare Sector # 544
Overall # 3648

Revenue TTM Y/Y Growth Statistics
High Average Low
2193.36 %
277.8 %
-93.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 205
Sector # 549
S&P 500 # 3670




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BLCM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Adaptimmune Therapeutics Plc-0.16%$ -0.164 millions
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc-0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Vycor Medical Inc -0.44%$ -0.442 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Hologic Inc-0.81%$ -0.808 millions
Bionexus Gene Lab Corp -0.83%$ -0.831 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions


About Bellicum Pharmaceuticals Inc Revenue Growth Rates (BLCM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Bellicum Pharmaceuticals Inc (CIK 1358403).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-23-038953
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Bellicum Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.